Hijiya, N. Et Al. 2021. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.. Blood advances , vol.5 , 2925-2934.

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., ... Kang, H. J.(2021). A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.. Blood advances , vol.5, 2925-2934.

Hijiya, Nobuko Et Al. "A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.," Blood advances , vol.5, 2925-2934, 2021

Hijiya, Nobuko Et Al. "A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.." Blood advances , vol.5, pp.2925-2934, 2021

Hijiya, N. Et Al. (2021) . "A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.." Blood advances , vol.5, pp.2925-2934.

@article{article, author={Nobuko Hijiya Et Al. }, title={A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.}, journal={Blood advances}, year=2021, pages={2925-2934} }